The SISAQOL Consortium aims to provide recommendations to standardize the analysis of patient reported outcome data in cancer RCTs.
Measures of health-related quality of life (HRQoL) and other patient-reported outcomes (PRO) generate important data in cancer randomized controlled trials (RCTs) to assist in evaluating the risks and benefits of cancer therapies, and fostering patient-centered cancer care.
However, the various ways these measures are analyzed and interpreted make it difficult to compare results across trials. This hinders the application of research findings to inform publications, product labelling, clinical guidelines and health policy.
To address these problems, the Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) initiative was established.
This international multidisciplinary consortium, directed by the European Organisation for Research and Treatment of Cancer (EORTC), was convened to provide recommendations to standardize the analysis of HRQoL and other PRO data in cancer RCTs.
Third SISAQOL-IMI Consensus Meeting
23 and 24 May 2023
On the 23-24 of May, 2023 the SISAQOL-IMI consortium will gather in Portugal for the third SISAQOL-IMI consensus meeting.
On the 23-24 of May, 2023 the SISAQOL-IMI consortium will gather for the third SISAQOL-IMI consensus meeting at the Hotel Pestana Cidadela in Cascais, Portugal.
SISAQOL-IMI aims to generate international recommendations on how to analyse, interpret and present patient reported outcome (PRO) data collected in cancer clinical trials. All recommendations generated by SISAQOL-IMI go through an elaborate consensus process where they get discussed and voted on by all 41 stakeholders, including, regulators, health technology assessment bodies, payers, clinicians, methodological and applied statisticians, PRO experts, industry, and patient organisations.
About the consensus meeting
The third SISAQOL-IMI consensus meeting aims to reach consensus on the final set of recommendation statements coming from work 2, 3, 4 and 6.
- Work package 2: Randomized controlled trials (RCT)
- Work package 3: Single arm studies
- Work package 4: Graphical presentation
- Work package 6: Clinically meaningful change
Similar to the consensus procedure followed at the second (virtual) consensus meeting, work package leaders will present a summary of the results from the pre-consensus meeting survey (1st round of voting) and suggest revisions and/or respond to comments. Then, the floor will be opened for discussion for each statement. Following the discussion, re-voting (2nd round of voting) will take place where the main representative from each organisation will submit their votes. A real-time voting tool will be used for re-voting during the meeting and results will be available immediately. By the end of the consensus process, it is hoped that the consortium will have a set of recommendations to take forward.
PLEASE NOTE: THIS IS A CLOSED MEETING BY INVITATION ONLY.
Find further practical information about the meeting here.
If you have any questions about the meeting or SISAQOL-IMI please contact sisaqolimi@eortc.org and Monika Turek.